As China continues to solidify its position as a global biotech hub, BIOCHINA 2025 promises to be a pivotal event for connecting exhibitors with top-tier Chinese companies such as BeiGene and Henlius.

In this exclusive interview with BioPharma APAC, Vera Deng, CEO of Enmore Bio, highlights the event's focus on cutting-edge sectors like ADCs, cell therapy, and gene therapy, and explains how BIOCHINA is driving international collaborations and innovation within the bio-industry.

How do exhibitors plan to connect with leading companies like BeiGene and Henlius during BIOCHINA 2025?

BIOCHINA is an international convention that connects various sectors of the bio-industry, promoting a cohesive ecosystem. The exhibitors primarily include service providers and upstream suppliers, such as those offering raw materials, reagents, consumables, and instruments. Notably, CROs and CDMOs also participate as exhibitors, engaging with top-tier Chinese pharma and biotech companies through exhibition booths, partnering meetings, and networking events.

The conference features speakers from leading Chinese biotech and biopharmaceutical companies like BeiGene and Henlius, with executives participating as panelists and keynote speakers. This involvement attracts key decision-makers, fostering valuable discussions and collaborations. As China’s leading communication platform in the bio-industry, BIOCHINA is dedicated to connecting innovators and enabling the growth of the bio-industry.

How are the products and services showcased at BIOCHINA 2025 aligned with the growing focus on ADCs, cell therapy, and gene therapy?

ADCs and cell and gene therapies are one of the most advanced industries in China today. As outlined in our BIOCHINA 25 Agenda, we will feature both technical and industrial forums covering various industries, including ADCs, cell and gene therapy, small molecular drugs, peptide drugs, and extra.

The technical forums will primarily focus on early-stage drug development, encompassing preclinical and clinical phases, with topics centered on technology of CMC. This format aims to facilitate in-depth discussions and promote knowledge sharing within these rapidly evolving fields.

What key partnerships or collaborations are expected to emerge from  BIOCHINA 2025?

To enhance business development and licensing at BIOCHINA, multinational corporations (MNCs) will present their Chinese market strategies, supported by strong delegations from both Chinese representatives and their headquarters. In 2024, participants included Roche, Pfizer, Novo Nordisk, Eli Lilly, and Boehringer Ingelheim.

With the involvement of 3,000 Chinese biotech companies and nearly 500 biotech upstream suppliers, BIOCHINA fosters international partnerships and collaborations across the entire supply chain and business development spectrum. BIOCHINA represents the latest advancements in the Chinese bio-industry.

What new technologies and innovations will be highlighted at BIOCHINA 2025?

BIOCHINA will showcase the most advanced fields of Nuclear Drugs, Peptide Drugs, Cell and Gene Therapy, Nucleic Acid Drugs, and Small Molecular Drugs. These industries will be well-represented in both technical and industrial forums. For 2025, the agenda will expand to include more content on Nuclear Drugs and Peptide Drugs, as both sectors are experiencing rapid growth in China. Key players involved in these industries will actively participate in the discussions.

How are companies expanding their presence in China’s biopharma market through participation in BIOCHINA 2025?

BIOCHINA is recognized as a premier platform for advancing China's bio-industry through collaboration and innovation. It is built around four core components—Exhibition, Conference, Partnering, and Networking—designed to facilitate meaningful connections and foster collaborations within the Chinese bio-industry. By participating in these events, international companies gain direct access to the Chinese bio sector and its key decision-makers. Additionally, the roadshow offers opportunities for international companies seeking business development and funding from Chinese biotech leaders and investors.